Highbridge Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Highbridge Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,932	Closed	-$435K	–	1534
2017 Q2	$437K	Buy	+1,932	New	+$421K	0.01%	798
2016 Q1	–	Sell	-2,658	Closed	-$369K	–	1484
2015 Q4	$369K	Buy	+2,658	New	+$368K	0.01%	1104
2015 Q3	–	Sell	-25,198	Closed	-$3.79M	–	1535
2015 Q2	$3.79M	Buy	+25,198	New	+$3.6M	0.05%	360
2014 Q4	–	Sell	-3,069	Closed	-$348K	–	1175
2014 Q3	$348K	Buy	+3,069	New	+$364K	﹤0.01%	953
2013 Q4	–	Sell	-49,336	Closed	-$5.8M	–	1064
2013 Q3	$5.8M	Buy	49,336 +11,524	+30%	+$1.36M	0.06%	311
2013 Q2	$4.24M	Buy	+37,812	New	+$4.44M	0.04%	341

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HCM

Hitchwood Capital Management New York $184M AUM 3.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Highbridge Capital Management's BIO Position: Q3 2017 in Review

Highbridge Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2017, closing a stake of 1,932 shares — an estimated $435K sold.

Highbridge Capital Management first reported a position in BIO in Q2 2013 and held it in 6 quarters. The position peaked at $5.8M in Q3 2013. 271 funds tracked by Wall St. Rank hold BIO as of Q3 2017.

Highbridge Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2017 after selling out during the quarter.
Highbridge Capital Management sold 1,932 Bio-Rad Laboratories Class A shares in Q3 2017, an estimated $435K.
Highbridge Capital Management first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 6 quarters.
Highbridge Capital Management's Bio-Rad Laboratories Class A position peaked at $5.8M in Q3 2013.
271 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.